Retinal Vasculitis Secondary to Durvalumab

Ocular manifestations are very rarely reported as side effects to checkpoint inhibitors. We present a case of a 64-year-old Caucasian man in treatment with durvalumab for non-small-cell lung carcinoma who presented a retinal vasculitis with macular edema. After three boluses of methylprednisolone, t...

Descripción completa

Detalles Bibliográficos
Autores principales: R. Andrade, Antonio, Moll-Udina, Aina, Martin, Ruth, Cilveti, Esther, Subirà, Olaia, Disfetano, Laura, García-Arumí, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250381/
https://www.ncbi.nlm.nih.gov/pubmed/32508622
http://dx.doi.org/10.1159/000507609
_version_ 1783538752123043840
author R. Andrade, Antonio
Moll-Udina, Aina
Martin, Ruth
Cilveti, Esther
Subirà, Olaia
Disfetano, Laura
García-Arumí, Jose
author_facet R. Andrade, Antonio
Moll-Udina, Aina
Martin, Ruth
Cilveti, Esther
Subirà, Olaia
Disfetano, Laura
García-Arumí, Jose
author_sort R. Andrade, Antonio
collection PubMed
description Ocular manifestations are very rarely reported as side effects to checkpoint inhibitors. We present a case of a 64-year-old Caucasian man in treatment with durvalumab for non-small-cell lung carcinoma who presented a retinal vasculitis with macular edema. After three boluses of methylprednisolone, the retinal vasculitis resolved and macular edema improved during follow-up. There was no need for durvalumab to be withdrawn.
format Online
Article
Text
id pubmed-7250381
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-72503812020-06-04 Retinal Vasculitis Secondary to Durvalumab R. Andrade, Antonio Moll-Udina, Aina Martin, Ruth Cilveti, Esther Subirà, Olaia Disfetano, Laura García-Arumí, Jose Case Rep Ophthalmol Case Report Ocular manifestations are very rarely reported as side effects to checkpoint inhibitors. We present a case of a 64-year-old Caucasian man in treatment with durvalumab for non-small-cell lung carcinoma who presented a retinal vasculitis with macular edema. After three boluses of methylprednisolone, the retinal vasculitis resolved and macular edema improved during follow-up. There was no need for durvalumab to be withdrawn. S. Karger AG 2020-05-05 /pmc/articles/PMC7250381/ /pubmed/32508622 http://dx.doi.org/10.1159/000507609 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
R. Andrade, Antonio
Moll-Udina, Aina
Martin, Ruth
Cilveti, Esther
Subirà, Olaia
Disfetano, Laura
García-Arumí, Jose
Retinal Vasculitis Secondary to Durvalumab
title Retinal Vasculitis Secondary to Durvalumab
title_full Retinal Vasculitis Secondary to Durvalumab
title_fullStr Retinal Vasculitis Secondary to Durvalumab
title_full_unstemmed Retinal Vasculitis Secondary to Durvalumab
title_short Retinal Vasculitis Secondary to Durvalumab
title_sort retinal vasculitis secondary to durvalumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250381/
https://www.ncbi.nlm.nih.gov/pubmed/32508622
http://dx.doi.org/10.1159/000507609
work_keys_str_mv AT randradeantonio retinalvasculitissecondarytodurvalumab
AT molludinaaina retinalvasculitissecondarytodurvalumab
AT martinruth retinalvasculitissecondarytodurvalumab
AT cilvetiesther retinalvasculitissecondarytodurvalumab
AT subiraolaia retinalvasculitissecondarytodurvalumab
AT disfetanolaura retinalvasculitissecondarytodurvalumab
AT garciaarumijose retinalvasculitissecondarytodurvalumab

Ejemplares similares